Our Goal is to Discover and Develop Best-in-Class Kv7.2/7.3 Activators
for the treatment of epilepsy and other disorders of the central nervous system. In order to do that, we would like to stay in touch with you.
Our Goal is to Discover and Develop Best-in-Class Kv7.2/7.3 Activators
for the treatment of epilepsy and other disorders of the central nervous system. In order to do that, we would like to stay in touch with you.
Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.